Raymond James initiated coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a report issued on Monday, The Fly reports. The brokerage set a “buy” rating and a $13.00 price target on the biotechnology company’s stock. Raymond James’ price target indicates a potential upside of 89.78% from the company’s previous close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.